- Home
- IMNM vs EH Comparison
IMNM vs EH Comparison
Compare IMNM & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- EH
- Stock Information
- Founded
- IMNM 2006
- EH 2014
- Country
- IMNM United States
- EH China
- Employees
- IMNM N/A
- EH N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- EH Military/Government/Technical
- Sector
- IMNM Health Care
- EH Industrials
- Exchange
- IMNM Nasdaq
- EH Nasdaq
- Market Cap
- IMNM 1.2B
- EH 1.4B
- IPO Year
- IMNM 2020
- EH 2019
- Fundamental
- Price
- IMNM $18.12
- EH $14.87
- Analyst Decision
- IMNM Strong Buy
- EH Strong Buy
- Analyst Count
- IMNM 8
- EH 3
- Target Price
- IMNM $25.75
- EH $24.80
- AVG Volume (30 Days)
- IMNM 1.4M
- EH 1.0M
- Earning Date
- IMNM 11-06-2025
- EH 11-28-2025
- Dividend Yield
- IMNM N/A
- EH N/A
- EPS Growth
- IMNM N/A
- EH N/A
- EPS
- IMNM N/A
- EH N/A
- Revenue
- IMNM $9,679,000.00
- EH $65,001,814.00
- Revenue This Year
- IMNM N/A
- EH $16.19
- Revenue Next Year
- IMNM $85.36
- EH $81.43
- P/E Ratio
- IMNM N/A
- EH N/A
- Revenue Growth
- IMNM N/A
- EH 87.04
- 52 Week Low
- IMNM $5.15
- EH $12.02
- 52 Week High
- IMNM $18.79
- EH $29.76
- Technical
- Relative Strength Index (RSI)
- IMNM 64.32
- EH 30.07
- Support Level
- IMNM $16.11
- EH $15.54
- Resistance Level
- IMNM $17.94
- EH $16.86
- Average True Range (ATR)
- IMNM 1.26
- EH 0.75
- MACD
- IMNM 0.02
- EH -0.25
- Stochastic Oscillator
- IMNM 86.56
- EH 1.43
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.